Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair
Authors
Keywords
-
Journal
Cancer Management and Research
Volume Volume 12, Issue -, Pages 4429-4439
Publisher
Informa UK Limited
Online
2020-06-10
DOI
10.2147/cmar.s254412
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging roles of and therapeutic strategies targeting BRD4 in cancer
- (2019) Mary E. White et al. CELLULAR IMMUNOLOGY
- The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
- (2019) Aubrey L. Miller et al. EBioMedicine
- HSP90 regulates osteosarcoma cell apoptosis by targeting the p53/TCF‐1‐mediated transcriptional network
- (2019) Jie Yang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells
- (2018) Julius C. Enßle et al. CANCER LETTERS
- Biological aspects of chondrosarcoma: Leaps and hurdles
- (2018) Benoîte Mery et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
- (2018) Linglong Yin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- BRD4 and MYC—clarifying regulatory specificity
- (2018) Arianna Sabò et al. SCIENCE
- Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
- (2018) Alexander S. Hölscher et al. Clinical Epigenetics
- BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy
- (2018) C. Mio et al. INTERNATIONAL JOURNAL OF CANCER
- Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
- (2018) Wei Meng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Novel therapeutic approaches in chondrosarcoma
- (2017) Genovefa Polychronidou et al. Future Oncology
- RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
- (2017) Mariam Gachechiladze et al. INTERNATIONAL JOURNAL OF CANCER
- The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling
- (2017) Huan-Tian Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells
- (2017) Harry O. King et al. Stem Cell Reports
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
- (2016) J. Shahbazi et al. CLINICAL CANCER RESEARCH
- Molecular oncogenesis of chondrosarcoma
- (2016) Frank M. Speetjens et al. CURRENT OPINION IN ONCOLOGY
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- Targeting survivin as a potential new treatment for chondrosarcoma of bone
- (2016) Y de Jong et al. Oncogenesis
- Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies
- (2015) Jordi Carreras Puigvert et al. FEBS Journal
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
- (2015) E. Q. Lee et al. NEURO-ONCOLOGY
- DNA repair mechanisms in cancer development and therapy
- (2015) Alessandro Torgovnick et al. Frontiers in Genetics
- Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells
- (2014) Huan-Tian Zhang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Outcome of advanced, unresectable conventional central chondrosarcoma
- (2014) Annemiek M. van Maldegem et al. CANCER
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
- (2014) Trent Fowler et al. PLoS One
- OpenComet: An automated tool for comet assay image analysis
- (2014) Benjamin M. Gyori et al. Redox Biology
- Advanced chondrosarcomas: role of chemotherapy and survival
- (2013) A. Italiano et al. ANNALS OF ONCOLOGY
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues
- (2013) Moritz Birkelbach et al. Journal of Thoracic Oncology
- Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
- (2013) Z Zou et al. ONCOGENE
- HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
- (2013) J E Bolden et al. Cell Death & Disease
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance
- (2011) J. G. van Oosterwijk et al. ANNALS OF ONCOLOGY
- Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
- (2011) K Ted Thurn et al. Future Oncology
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
- (2010) Julia M. Wagner et al. Clinical Epigenetics
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started